656 related articles for article (PubMed ID: 28917206)
1. Maternal and infant outcomes following third trimester exposure to marijuana in opioid dependent pregnant women maintained on buprenorphine.
O'Connor AB; Kelly BK; O'Brien LM
Drug Alcohol Depend; 2017 Nov; 180():200-203. PubMed ID: 28917206
[TBL] [Abstract][Full Text] [Related]
2. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy.
Jones HE; Dengler E; Garrison A; O'Grady KE; Seashore C; Horton E; Andringa K; Jansson LM; Thorp J
Drug Alcohol Depend; 2014 Jan; 134():414-417. PubMed ID: 24290979
[TBL] [Abstract][Full Text] [Related]
3. Maternal buprenorphine treatment and infant outcome.
Jansson LM; Velez ML; McConnell K; Spencer N; Tuten M; Jones H; Rios R; King VL; Gandotra N; Millio L; DiPietro JA
Drug Alcohol Depend; 2017 Nov; 180():56-61. PubMed ID: 28869859
[TBL] [Abstract][Full Text] [Related]
4. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication.
Kaltenbach K; Holbrook AM; Coyle MG; Heil SH; Salisbury AL; Stine SM; Martin PR; Jones HE
Addiction; 2012 Nov; 107 Suppl 1(0 1):45-52. PubMed ID: 23106926
[TBL] [Abstract][Full Text] [Related]
5. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy.
O'Connor AB; Collett A; Alto WA; O'Brien LM
J Midwifery Womens Health; 2013; 58(4):383-8. PubMed ID: 23931660
[TBL] [Abstract][Full Text] [Related]
6. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women.
Metz V; Jagsch R; Ebner N; Würzl J; Pribasnig A; Aschauer C; Fischer G
Hum Psychopharmacol; 2011 Aug; 26(6):412-21. PubMed ID: 21823171
[TBL] [Abstract][Full Text] [Related]
7. Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome.
Tolia VN; Murthy K; Bennett MM; Miller ES; Benjamin DK; Smith PB; Clark RH
J Perinatol; 2018 Jan; 38(1):75-79. PubMed ID: 29048415
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison.
Unger A; Jagsch R; Jones H; Arria A; Leitich H; Rohrmeister K; Aschauer C; Winklbaur B; Bäwert A; Fischer G
Addiction; 2011 Jul; 106(7):1355-62. PubMed ID: 21438938
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data.
Debelak K; Morrone WR; O'Grady KE; Jones HE
Am J Addict; 2013; 22(3):252-4. PubMed ID: 23617867
[TBL] [Abstract][Full Text] [Related]
10. The relationship between gestational age and the severity of neonatal abstinence syndrome.
Gibson KS; Stark S; Kumar D; Bailit JL
Addiction; 2017 Apr; 112(4):711-716. PubMed ID: 27886650
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
Wachman EM; Saia K; Miller M; Valle E; Shrestha H; Carter G; Werler M; Jones H
Clin Ther; 2019 Sep; 41(9):1681-1689. PubMed ID: 31358302
[TBL] [Abstract][Full Text] [Related]
12. Maternal Buprenorphine Dose at Delivery and Its Relationship to Neonatal Outcomes.
O'Connor AB; O'Brien L; Alto WA
Eur Addict Res; 2016; 22(3):127-30. PubMed ID: 26491960
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
Kelty E; Hulse G
Drugs; 2017 Jul; 77(11):1211-1219. PubMed ID: 28536981
[TBL] [Abstract][Full Text] [Related]
14. Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population.
Jumah NA; Edwards C; Balfour-Boehm J; Loewen K; Dooley J; Gerber Finn L; Kelly L
BMJ Open; 2016 Oct; 6(10):e011774. PubMed ID: 27799240
[TBL] [Abstract][Full Text] [Related]
15. Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway.
Nechanská B; Mravčík V; Skurtveit S; Lund IO; Gabrhelík R; Engeland A; Handal M
Addiction; 2018 Jul; 113(7):1286-1294. PubMed ID: 29443414
[TBL] [Abstract][Full Text] [Related]
16. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study.
Bakstad B; Sarfi M; Welle-Strand GK; Ravndal E
Eur Addict Res; 2009; 15(3):128-34. PubMed ID: 19332991
[TBL] [Abstract][Full Text] [Related]
17. Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome.
Pritham UA; Paul JA; Hayes MJ
J Obstet Gynecol Neonatal Nurs; 2012 Mar; 41(2):180-190. PubMed ID: 22375882
[TBL] [Abstract][Full Text] [Related]
18. Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome.
Winhusen T; Wilder C; Wexelblatt SL; Theobald J; Hall ES; Lewis D; Van Hook J; Marcotte M
Contemp Clin Trials; 2014 Sep; 39(1):158-65. PubMed ID: 25183042
[TBL] [Abstract][Full Text] [Related]
19. Use of naltrexone in treating opioid use disorder in pregnancy.
Towers CV; Katz E; Weitz B; Visconti K
Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
[TBL] [Abstract][Full Text] [Related]
20. Does Maternal Buprenorphine Dose Affect Severity or Incidence of Neonatal Abstinence Syndrome?
Wong J; Saver B; Scanlan JM; Gianutsos LP; Bhakta Y; Walsh J; Plawman A; Sapienza D; Rudolf V
J Addict Med; 2018; 12(6):435-441. PubMed ID: 29905586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]